Collaborators


  • A key advisor for VisionGate is Decus Biomedical (San Francisco, CA), a company that consults with biomedical companies seeking FDA certification for their products. VisionGate has a longstanding relationship with the President of Decus, Dr. Grace Bartoo, with whom we have worked in prior companies and on prior applications to bring products to market.
  • Dr. Terry Urbine, University of Arizona College of Pharmacy, has helped VisionGate assess the economics of the LuCED® lung test. We will soon submit a publication to the high-impact factor journal, American Journal of Managed Care, that shows cost efficacy of the LuCED test.
  • Dr. Gregory Yang, Yuma Regional Cancer Center (Thoracic Group), has become increasingly valuable as a partner to supply specimens for the LuCED lung test development and clinical work. Upcoming research could take a number of important directions that may pair genomics profiling for lung cancer risk with the LuCED test.
  • Arizona State University’s Biodesign Institute also owns an earlier Cell-CT™ system and our efforts are in alignment.

Below are collaborators who have supplied specimens for VisionGate’s work:

  • Kaiser Permanente, Oakland (Dr. George Minowada)
  • Fred Hutchinson Cancer Research Center, Seattle (Dr. Peter Nelson)
  • The University of Navarra, Spain (Dr. Javier Zulueta)
  • University of Colorado, Denver (Dr. York Miller)
  • Cornell University, Ithaca (Dr. Anthony Reeves)
  • New Orleans VA, New Orleans (Dr. Jaime Palomino)
  • St. Joseph’s Hospital and Medical Center, Phoenix (Dr. Elbert Kuo)
  • University of Washington, Seattle (Dr. Rodney Schmidt)
  • Swedish Cancer Institute, Seattle (Dr. Ralph Aye)
  • University of Liverpool, England (Dr. John Field)
  • VU University, Netherlands (Dr. Eric Thunnissen)
  • University Medical Center of Groningen, Netherlands (Dr. Matthijs Oudkerk)
  • University of Toronto, Canada (Dr. Heidi Roberts)
  • Baptist Cancer Institute, Florida (Dr. Douglas Johnson)
  • General Hospital Aristotle University of Thessaloniki, Greece (Dr. Konstantinos Zarogoulidis)
  • Sheba Medical Center, Israel (Dr. Nir Peled)

This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2017 - VisionGate, Inc.